<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01579461</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-039</org_study_id>
    <secondary_id>2008-000210-77</secondary_id>
    <nct_id>NCT01579461</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects</brief_title>
  <official_title>An Open Label Single Dose Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of YM178 Compared With Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to investigate and compare the effect of Mirabegron (YM178) on subjects with
      mild and moderate hepatic impairment compared to healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy subjects and subjects with mild and moderate hepatic impairment are admitted on Day
      1. Subjects receive a single oral dose of Mirabegron in the morning of Day 1 and will remain
      in the unit till Day 5 with outpatient visits on Days 6 and 7 for healthy subjects and Days
      6, 7, 9 and 11 for subjects with hepatic impairment. Blood sampling for PK assessment will be
      up to 144 hrs post dose for healthy subjects and up to 240 hrs post dose for subjects with
      hepatic impairment. An additional blood sample was obtained for all subjects 4 hrs post dose
      for protein binding.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the single dose pharmacokinetics of Mirabegron in healthy subjects compared to subjects with hepatic impairment</measure>
    <time_frame>Day 1 - Day 11</time_frame>
    <description>AUCinf and Cmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by incidence of adverse events, lab tests, physical exam, ECG and vital signs</measure>
    <time_frame>Day 1 - End of Study (Up to Day 19)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Healthy Subjects</condition>
  <condition>Mild and Moderate Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers (matched with mild hepatic)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers (matched with moderate hepatic)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirabegron</intervention_name>
    <description>oral</description>
    <arm_group_label>mild hepatic impairment</arm_group_label>
    <arm_group_label>moderate hepatic impairment</arm_group_label>
    <arm_group_label>healthy volunteers (matched with mild hepatic)</arm_group_label>
    <arm_group_label>healthy volunteers (matched with moderate hepatic)</arm_group_label>
    <other_name>YM178</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index more than or equal to 18.0 and less than 32.0 kg/m2 (men and women)

          -  Subject is genotyped as an extensive metabolizer for CYP2D6

          -  For subjects with mild/moderate hepatic impairment: Hepatic dysfunction scored as mild
             impairment ((between 5-6 in the Child-Pugh's classification) and moderate impairment
             (between 7-9 in the Child-Pugh's classification)

          -  Healthy subject with normal hepatic function

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to mirabegron or any components of the
             formulations used

          -  A marked prolongation at screening of QT/QTC interval demonstrated by a mean QTcF
             interval &gt;450 ms for male subjects and a mean QTcF interval &gt;470 ms for female
             subjects (based on 3 ECGs)

          -  Abnormal pulse rate and/or blood pressure measurements at the pre-study visit taken in
             triplicate by means of an automatic device, after subject has been resting in supine
             position for 5 min: •Pulse rate &lt;40 or &gt;90 bpm; Mean systolic blood pressure &lt;90 or
             &gt;160 mmHg; Mean diastolic blood pressure &lt;40 or &gt;95 mmHg

          -  Healthy subjects: use of any prescribed or OTC drugs (except paracetamol, with a
             maximum of 3g/day) in the 2 weeks prior to admission to the clinical unit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FNsP Bratislava, nemocnica akad. L. Dérera; Klinika pracovného lekárstva a toxikológie</name>
      <address>
        <city>Bratislava</city>
        <zip>83305</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=797</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <reference>
    <citation>Dickinson J, Lewand M, Sawamoto T, Krauwinkel W, Schaddelee M, Keirns J, Kerbusch V, Moy S, Meijer J, Kowalski D, Morton R, Lasseter K, Riff D, Kupčová V, van Gelderen M. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron. Clin Drug Investig. 2013 Jan;33(1):11-23. doi: 10.1007/s40261-012-0031-3.</citation>
    <PMID>23208320</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2012</study_first_submitted>
  <study_first_submitted_qc>April 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2012</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>mirabegron</keyword>
  <keyword>hepatic impairment</keyword>
  <keyword>Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

